H.C. Wainwright analyst Edward White lowered the firm’s price target on Inozyme to $14 from $16 and keeps a Buy rating on the shares. The analyst moved the estimated launch of ENPP1 to 2027 and the estimated launch of ABCC6 to 2028 following the topline data from the Phase 1/2 trial in adults with ABCC6 deficiency release.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma Advances with Promising INZ-701 Trial Results
- Inozyme announces ‘positive’ results from Phase 1/2 trials of INZ-701
- Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
